| http://www.w3.org/ns/prov#value | - Patients with a variety of cancer types have been studied in the Phase 1 trial, including patients with renal cell carcinoma, melanoma, colorectal cancer, sarcoma, breast cancer, non-small cell lung cancer, and other cancers, said John L. Marshall, M.D., Director, Developmental Therapeutics and Associate Professor of Medicine at LCCC. Over 250 total doses have been administered to these refract
|
